Drugs & Targets FDA expands approval of Yervoy to include pediatric patients 12 years and older with unresectable or metastatic melanoma July 28, 2017Vol.43 No.30
Drugs & Targets FDA accepts BMS applications for Opdivo four-week dosing schedule across approved indications July 28, 2017Vol.43 No.30
Drugs & Targets Novartis receives positive CHMP opinion for Rydapt for newly diagnosed FLT3-mutated AML, three types of advanced systemic mastocytosis July 28, 2017Vol.43 No.30
Drugs & TargetsFree FDA approves treatment to reduce risk of breast cancer returning July 21, 2017Vol.43 No.29
Drugs & TargetsFree FDA accepts for priority review BMS application for dasatinib in children with CP Ph+ CML July 21, 2017Vol.43 No.29
Drugs & Targets FDA converts accelerated approval of Amgen’s Blincyto to full approval in ALL July 14, 2017Vol.43 No.28
Drugs & Targets FDA places clinical hold on Merck’s three Keytruda multiple myeloma studies July 14, 2017Vol.43 No.28
Drugs & TargetsFree FDA clears cooling cap treatment in solid tumor chemotherapy July 07, 2017Vol.43 No.27
Drugs & TargetsFree FDA granted marketing approval to the Praxis Extended RAS Panel July 07, 2017Vol.43 No.27
